Do statins beneficially or adversely affect glucose homeostasis?

Current Vascular Pharmacology

Volumn 8, Issue 5, 2010, Pages 612-631

  Kostapanos, Michael S ^a   Liamis, George L ^a   Milionis, Haralampos J ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Diabetes; Glucose; Insulin resistance; Insulin sensitivity; Statins

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; AMLODIPINE; ATORVASTATIN; CERIVASTATIN; FARNESYL DIPHOSPHATE; FENOFIBRATE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LEPTIN; MEVINOLIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PITAVASTATIN; PLACEBO; PRAVASTATIN; RESISTIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADIPOCYTE; ANTIINFLAMMATORY ACTIVITY; BLOOD FLOW; CARBOHYDRATE METABOLISM; CLINICAL STUDY; DRUG EFFECT; DRUG POTENCY; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOMODULATION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPOPHILICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRESCRIPTION; REVIEW; RISK; VASCULARIZATION; ANIMAL; CHEMICAL PHENOMENA; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COMPARATIVE STUDY; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HOMEOSTASIS; PANCREAS; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; GLUCOSE INTOLERANCE; HOMEOSTASIS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOMODULATION; INSULIN RESISTANCE; PANCREAS; RISK FACTORS;

EID: 78651085122     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016110792006879     Document Type: Review

References (140)

1. Jones PH. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options. Am Heart J 2004; 148(1 Suppl): S9-13.
2. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
3. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
4. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
6. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-62.
7. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32: 1924-9.
8. Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. Diabetes Res Clin Pract 2010; 87: 98-107.
9. Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006; 13: 123-9.
10. Kostapanos MS, Milionis HJ, Elisaf MS. An overview of the extralipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther 2008; 13: 157-74.
11. Favaro E, Miceli I, Bussolati B, et al. Hyperglycemia induces apoptosis of human pancreatic islet endothelial cells: effects of pravastatin on the Akt survival pathway. Am J Pathol 2008; 173: 442-50.
12. Huang Z, Jansson L, Sjoholm A. Pancreatic islet blood flow is selectively enhanced by captopril, irbesartan and pravastatin, and suppressed by palmitate. Biochem Biophys Res Commun 2006; 346: 26-32.
13. Huang Z, Jansson L, Sjoholm A. Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats. Clin Sci (Lond) 2007; 112: 69-76.
14. Huang Z, Jansson L, Sjoholm A. Gender-specific regulation of pancreatic islet blood flow, insulin levels and glycaemia in spontaneously diabetic Goto-Kakizaki rats. Clin Sci (Lond) 2008; 115: 35-42.
15. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999; 126: 1205-13.
16. Xia F, Xie L, Mihic A, et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology 2008; 149: 5136-45.
17. Li G, Regazzi R, Roche E, Wollheim CB. Blockade of mevalonate production by lovastatin attenuates bombesin and vasopressin potentiation of nutrient-induced insulin secretion in HIT-T15 cells. Probable involvement of small GTP-binding proteins. Biochem J 1993; 289 (Pt 2): 379-85.
18. Amin R, Chen HQ, Tannous M, Gibbs R, Kowluru A. Inhibition of glucose- and calcium-induced insulin secretion from betaTC3 cells by novel inhibitors of protein isoprenylation. J Pharmacol Exp Ther 2002; 303: 82-8.
19. Metz SA, Rabaglia ME, Stock JB, Kowluru A. Modulation of insulin secretion from normal rat islets by inhibitors of the posttranslational modifications of GTP-binding proteins. Biochem J 1993; 295 (Pt 1): 31-40.
20. Bliznakov EG. Diabetes and the role of isoprenoid biosynthesis. FEBS Lett 2002; 525: 169-70.
21. Langin D. Diabetes, insulin secretion, and the pancreatic beta-cell mitochondrion. N Engl J Med 2001; 345: 1772-4.
22. Ishikawa M, Okajima F, Inoue N, et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a betacell line, MIN6 cells. J Atheroscler Thromb 2006; 13: 329-35.
23. Elmendorf JS, Pessin JE. Insulin signaling regulating the trafficking and plasma membrane fusion of GLUT4-containing intracellular vesicles. Exp Cell Res 1999; 253: 55-62.
24. Khan AH, Pessin JE. Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia 2002; 45: 1475-83.
25. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001; 507: 357-61.
26. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49: 1881-92.
27. Mauser W, Perwitz N, Meier B, Fasshauer M, Klein J. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur J Pharmacol 2007; 564: 37-46.
28. Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J Pharmacol Sci 2008; 107: 80-9.
29. Horvath EM, Tackett L, Elmendorf JS. A novel membrane-based anti-diabetic action of atorvastatin. Biochem Biophys Res Commun 2008; 372: 639-43.
30. Horvath EM, Tackett L, McCarthy AM, Raman P, Brozinick JT, Elmendorf JS. Antidiabetogenic effects of chromium mitigate hyperinsulinemia- induced cellular insulin resistance via correction of plasma membrane cholesterol imbalance. Mol Endocrinol 2008; 22: 937-50.
31. Chen G, Liu P, Pattar GR, et al. Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol Endocrinol 2006; 20: 857-70.
32. Rigalleau V, Beylot M, Pachiaudi C, Guillot C, Deleris G, Gin H. Mechanisms of glucose intolerance during triglyceride infusion. Am J Physiol 1998; 275: E641-648.
33. Boden G, Jadali F, White J, et al. Effects of fat on insulinstimulated carbohydrate metabolism in normal men. J Clin Invest 1991; 88: 960-6.
34. Kelley DE, Mokan M, Simoneau JA, Mandarino LJ. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J Clin Invest 1993; 92: 91-8.
35. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97: 2859-65.
36. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006; 2: 335-48.
37. Costa A, Casamitjana R, Casals E, et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and Creactive protein in subjects with impaired fasting glucose. Diabet Med 2003; 20: 743-5.
38. Paolisso G, Barbagallo M, Petrella G, et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000; 150: 121-7.
39. Huptas S, Geiss HC, Otto C, Parhofer KG. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol 2006; 98: 66-9.
40. Paniagua JA, Lopez-Miranda J, Escribano A, et al. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. Diabetes 2002; 51: 2596-603.
41. Paolisso G, Sgambato S, De Riu S, et al. Simvastatin reduces plasma lipid levels and improves insulin action in elderly, noninsulin dependent diabetics. Eur J Clin Pharmacol 1991; 40: 27-31.
42. Tanaka A, Yamada N, Saito Y, Kawakami M, Ohashi Y, Akanuma Y. A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia. Clin Chim Acta 2001; 312: 41-7.
43. Sasaki S, Kuwahara N, Kunitomo K, et al. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 2002; 89: 386-9.
44. Tikkanen MJ, Laakso M, Ilmonen M, et al. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Diabetes Care 1998; 21: 477-81.
45. Sane T, Knudsen P, Vuorinen-Markkola H, Yki-Jarvinen H, Taskinen MR. Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. Metabolism 1995; 44: 589-96.
46. Tenenbaum H, Behar S, Boyko V, et al. Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 2007; 194: 265-71.
47. Jeong S, Yoon M. Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat dietinduced obese mice. Exp Mol Med 2009; 41: 397-405.
48. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004; 50: 1511-25.
49. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-9.
50. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968-74.
51. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-92.
52. Sugiyama S, Fukushima H, Kugiyama K, et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007; 194: e43-51.
53. Takagi T, Matsuda M, Abe M, et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008; 196: 114-21.
54. Araki K, Masaki T, Katsuragi I, Kakuma T, Yoshimatsu H. Effects of pravastatin on obesity, diabetes, and adiponectin in diet-induced obese mice. Obesity (Silver Spring) 2008; 16: 2068-73.
55. Koh KK, Quon MJ, Han SH, et al. Simvastatin improves flowmediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008; 31: 776-82.
56. Forst T, Pfutzner A, Lubben G, et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism 2007; 56: 491-6.
57. Matafome P, Monteiro P, Nunes E, et al. Therapeutic association of atorvastatin and insulin in cardiac ischemia: study in a model of type 2 diabetes with hyperlipidemia. Pharmacol Res 2008; 58: 208-14.
58. Bayes B, Granada ML, Lauzurica R, et al. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients. Transplant Proc 2005; 37: 3808-12.
59. Suzuki M, Kakuta H, Takahashi A, et al. Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice. J Atheroscler Thromb 2005; 12: 77-84.
60. Gannage-Yared MH, Azar RR, Amm-Azar M, et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 2005; 54: 947-51.
61. Pfutzner A, Hanefeld M, Lubben G, et al. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk - results from the PIOSTAT study. Horm Metab Res 2007; 39: 764-8.
62. Sonmez A, Dogru T, Tasci I, et al. The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia. Clin Endocrinol (Oxf) 2006; 64: 567-72.
63. Gouni-Berthold I, Berthold HK, Chamberland JP, Krone W, Mantzoros CS. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf) 2008; 68: 536-41.
64. Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP. VISFATIN/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol 2010; 8: 12-28.
65. Kostapanos MS, Derdemezis CS, Filippatos TD, et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 2008; 578: 249-52.
66. Sader S, Nian M, Liu P. Leptin: a novel link between obesity, diabetes, cardiovascular risk, and ventricular hypertrophy. Circulation 2003; 108: 644-6.
67. Chu CH, Lee JK, Lam HC, et al. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes. J Endocrinol Invest 2008; 31: 42-7.
68. Bulcao C, Giuffrida FM, Ribeiro-Filho FF, Ferreira SR. Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity? Braz J Med Biol Res 2007; 40: 229-35.
69. Yu Y, Ohmori K, Chen Y, et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 2004; 44: 904-13.
70. Zhao SP, Wu ZH. Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits. Clin Chim Acta 2005; 360: 133-40.
71. Maeda T, Horiuchi N. Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation. J Biochem 2009; 145: 771-81.
72. Barnes KM, Miner JL. Role of resistin in insulin sensitivity in rodents and humans. Curr Protein Pept Sci 2009; 10: 96-107.
73. Chu CS, Lee KT, Lee MY, et al. Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia. Acta Cardiol 2006; 61: 263-9.
74. Otto C, Otto B, Frost RJ, et al. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol 2007; 44: 65-8.
75. Ichida Y, Hasegawa G, Fukui M, et al. Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/ macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes. Pharmacology 2006; 76: 34-9.
76. Hu WL, Qiao SB, Li JJ. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin. Cytokine 2007; 40: 201-6.
77. Shyu KG, Chua SK, Wang BW, Kuan P. Mechanism of inhibitory effect of atorvastatin on resistin expression induced by tumor necrosis factor-alpha in macrophages. J Biomed Sci 2009; 16: 50.
78. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-8.
79. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNFalpha function. Nature 1997; 389: 610-4.
80. Festa A, D'Agostino R, Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.
81. Abe M, Matsuda M, Kobayashi H, et al. Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88- independent IRF3/IFN-beta pathway in macrophages. Arterioscler Thromb Vasc Biol 2008; 28: 871-7.
82. Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur J Clin Pharmacol 2006; 62: 817-22.
83. Lalli CA, Pauli JR, Prada PO, et al. Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet. Metabolism 2008; 57: 57-65.
84. Miller AW, Tulbert CD, Busija DW. Rosuvastatin treatment reverses impaired coronary artery vasodilation in fructose-fed, insulin- resistant rats. Am J Physiol Regul Integr Comp Physiol 2004; 287: R157-160.
85. Naples M, Federico LM, Xu E, Nelken J, Adeli K. Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization. Atherosclerosis 2008; 198: 94-103.
86. ter Avest E, Abbink EJ, de Graaf J, Tack CJ, Stalenhoef AF. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest 2005; 35: 558-64.
87. Sharif A, Ravindran V, Moore R, et al. The effect of rosuvastatin on insulin sensitivity and pancreatic beta-cell function in nondiabetic renal transplant recipients. Am J Transplant 2009; 9: 1439-45.
88. Kostapanos MS, Milionis HJ, Filippatos TD, et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther 2007; 29: 1403-14.
89. Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol 2008; 590: 327-32.
90. Lamendola C, Abbasi F, Chu JW, et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. Am J Cardiol 2005; 95: 189-93.
91. Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract 2009; 63: 1308-13.
92. Mizukawa M, Ohmori K, Obayashi A, et al. Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model. Hypertens Res 2009; 32: 617-24.
93. Kanno H, Iwai M, Inaba S, et al. Improvement of glucose intolerance by combination of pravastatin and olmesartan in type II diabetic KK-A(y) mice. Hypertens Res 2009; 32: 706-11.
94. Chan P, Tomlinson B, Lee CB, Pan WH, Lee YS. Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects. Hypertension 1996; 28: 647-51.
95. Okada K, Maeda N, Kikuchi K, Tatsukawa M, Sawayama Y, Hayashi J. Pravastatin improves insulin resistance in dyslipidemic patients. J Atheroscler Thromb 2005; 12: 322-9.
96. Dagli N, Yavuzkir M, Karaca I. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 2007; 30: 230-5.
97. Lee WJ, Lee WL, Tang YJ, et al. Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia. Clin Chim Acta 2008; 390: 49-55.
98. Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26: 2713-21.
99. Galvan AQ, Natali A, Baldi S, et al. Effect of a reduced-fat diet with or without pravastatin on glucose tolerance and insulin sensitivity in patients with primary hypercholesterolemia. J Cardiovasc Pharmacol 1996; 28: 595-602.
100. Sheu WH, Shieh SM, Shen DD, et al. Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia. Am Heart J 1994; 127: 331-6.
101. Tajima N, Kurata H, Nakaya N, et al. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis 2008; 199: 455-62.
102. Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 2004; 58: 614-8.
103. Palomer X, Calpe-Berdiel L, Verdaguer J, et al. Atorvastatin does not decrease or delay diabetes onset in two different mouse models of type 1 diabetes. Diabetologia 2005; 48: 1671-3.
104. Wong V, Stavar L, Szeto L, et al. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis 2006; 184: 348-55.
105. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
106. Malik J, Melenovsky V, Wichterle D, et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate vs. atorvastatin trial--FAT). Cardiovasc Res 2001; 52: 290-8.
107. Karpisek M, Stejskal D, Kotolova H, et al. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur J Clin Invest 2007; 37: 637-42.
108. Avisar I, Brook JG, Wolfovitz E. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia. Eur J Intern Med 2008; 19: 203-8.
109. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002; 51: 334-42.
110. Akalin A, Temiz G, Akcar N, Sensoy B. Short term effects of atorvastatin on endothelial functions and oxidized LDL levels in patients with type 2 diabetes. Endocr J 2008; 55: 861-6.
111. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
112. Rydgren T, Vaarala O, Sandler S. Simvastatin protects against multiple low-dose streptozotocin-induced type 1 diabetes in CD-1 mice and recurrence of disease in nonobese diabetic mice. J Pharmacol Exp Ther 2007; 323: 180-5.
113. Altunbas H, Balci MK, Karayalcin U. No effect of simvastatin treatment on insulin sensitivity in patients with primary hypercholesterolemia. Endocr Res 2003; 29: 265-75.
114. Jula A, Marniemi J, Huupponen R, Virtanen A, Rastas M, Ronnemaa T. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 2002; 287: 598-605.
115. Hwu CM, Kwok CF, Chen HS, et al. Lack of effect of simvastatin on insulin sensitivity in type 2 diabetic patients with hypercholesterolaemia: results from a double-blind, randomized, placebocontrolled crossover study. Diabet Med 1999; 16: 749-54.
116. Nielsen S, Schmitz O, Moller N, et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulindependent) diabetic patients with microalbuminuria. Diabetologia 1993; 36: 1079-86.
117. Deegan P, Owens D, Collins P, Johnson A, Tomkin GH. Association between low-density lipoprotein composition and its metabolism in non-insulin-dependent diabetes mellitus. Metabolism 1999; 48: 118-24.
118. Farrer M, Winocour PH, Evans K, et al. Simvastatin in non-insulindependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. Diabetes Res Clin Pract 1994; 23: 111-9.
119. Szendroedi J, Anderwald C, Krssak M, et al. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. Diabetes Care 2009; 32: 209-14.
120. Sweany AE, Shapiro DR, Tate AC, Goldberg RB, Stein EA. Effects of simvastatin vs. gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. NIDDM Study Group. Clin Ther 1995; 17: 186-203.
121. Ohrvall M, Lithell H, Johansson J, Vessby B. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism 1995; 44: 212-7.
122. Kawai T, Tokui M, Funae O, et al. Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes. Diabetes Care 2005; 28: 2980-1.
123. McCrea JB, Fruncillo RJ, Holland SD, et al. Lovastatin does not affect oral glucose tolerance in hypercholesterolemic patients. J Clin Pharmacol 1993; 33: 581-5.
124. Goldberg R, La Belle P, Zupkis R, Ronca P. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus. Am J Cardiol 1990; 66: 16B-21B.
125. Hung YJ, Pei D, Wu DA, Kuo SW, Fuh MM, Jeng C. Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol. J Formos Med Assoc 1999; 98: 104-10.
126. Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther 2004; 26: 1599-607.
127. Sonmez A, Baykal Y, Kilic M, et al. Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients. Endocrine 2003; 22: 151-4.
128. Ishikawa M, Namiki A, Kubota T, et al. Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. Intern Med 2006; 45: 51-5.
129. Kurabayashi M, Yamazaki T. Superior benefit of aggressive lipidlowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy. J Atheroscler Thromb 2008; 15: 314-23.
130. Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009; 204: 483-90.
131. Ando H, Sugimoto K, Yanagihara H, et al. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients. Clin Exp Pharmacol Physiol 2008; 35:1012-17.
132. Takano T, Yamakawa T, Takahashi M, Kimura M, Okamura A. Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2006; 13: 95-100.
133. Mita T, Watada H, Nakayama S, et al. Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocr J 2007; 54: 441-7.
134. Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008; 15: 269-75.
135. Yokote K, Saito Y. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J Atheroscler Thromb 2009; 16: 297-98.
136. Kanda M, Satoh K, Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 2003; 26: 1681-84.
137. Satoh K, Keimatsu N, Kanda M, et al. HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats. Biol Pharm Bull 2005; 28: 2092-5.
138. Chen Y, Ohmori K, Mizukawa M, et al. Differential impact of atorvastatin vs. pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J 2007; 71: 144-52.
139. Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther 2008; 30: 1089-101.
140. Hunninghake DB, Ballantyne CM, Maccubbin DL, Shah AK, Gumbiner B, Mitchel YB. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther 2003; 25: 1670-86.